Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on March 29, 2005. The report discloses a specific corporate event under Regulation FD regarding the company's pharmaceutical product, BIAXIN XL.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on intellectual property updates.
Material Changes
On March 29, 2005, the United States Patent and Trademark Office issued a new patent for BIAXIN XL, the extended-release form of the antibiotic clarithromycin. Key details include:
- Patent Scope: The new patent covers the pharmacokinetic profile of BIAXIN XL, which enables more consistent blood levels of clarithromycin.
- Patent Duration: Formulation and pharmacokinetic patents for BIAXIN XL extend until 2017.
- Market Position: BIAXIN XL accounts for nearly 70 percent of all BIAXIN prescriptions in the U.S., according to IMS monthly reporting data.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on future earnings. The document notes that the information is furnished, not filed, and does not constitute an admission of materiality or completeness for investment decision-making purposes. The primary strategic implication is the strengthening of the intellectual property estate surrounding BIAXIN XL.
Investor Verification Checklist
- Verify the specific expiration date of the new patent (2017) and its coverage of pharmacokinetic profiles.
- Confirm the current market share of BIAXIN XL relative to BIAXIN IR (stated as nearly 70% of U.S. prescriptions).
- Review the full prescribing information for BIAXIN XL to understand the specific indications and adverse event profiles mentioned.
- Check subsequent filings for any financial impact analysis related to the extended patent protection.